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CASE REPORT
Response to sunitinib of a 
gastrointestinal stromal tumor with a rare exon 
12 PDGFRA mutation
Andrew S. Brohl1*, Elizabeth G. Demicco2, Karen Mourtzikos3 and Robert G. Maki4
Abstract 
Background: Gastrointestinal stromal tumors (GISTs) are commonly driven by activating mutations in either KIT or 
PDGFRA. Importantly, different mutations within these two genes can lead to very different levels of sensitivity or 
resistance to kinase inhibitor therapy. Due to rarity, sensitivity or resistance of exon 12 PDGFRA mutant GIST to kinase 
inhibitor therapy is not well defined.
Case summary: We report the case of a patient with a PDGFRA exon 12 mutated GIST. The patient experienced a 
very good response to imatinib in the neoadjuvant setting, but then relapsed while still on adjuvant imatinib. In this 
patient, we report a dramatic response to second line treatment with sunitinib, with complete resolution of two liver 
lesions at the time of first restaging.
Conclusions: This is the first report detailing a response to treatment with sunitinib of a gastrointestinal stromal 
tumor with an uncommon exon 12 PDGFRA mutation. Based on the observed efficacy, GIST patients with this rare 
molecular subtype should be considered for sunitinib therapy.
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Background
Gastrointestinal stromal tumors (GISTs) are commonly 
driven by activating mutations in either KIT or PDGFRA 
[1, 2]. These molecular targets have successfully been 
exploited by treatment with small molecule kinase inhibi-
tor therapy to dramatically impact clinical outcomes [3]. 
Importantly, different mutations within these two genes 
can lead to very different levels of sensitivity or resist-
ance to inhibitor therapy [4]. It is therefore essential for 
researchers and clinicians to keep an accurate catalog of 
how different mutations respond to therapeutics.
Occurring in only 5–7 % of GIST, PDGFRA mutations 
are by far the less common of the two driving kinase gene 
mutations in GIST. PDGFRA mutations are found pre-
dominantly in exons 18 (~5 %), 12 (~1 %) and 14 (<1 %), 
and over half of all PDGFRA mutations involve the same 
amino acid change in exon 18, D842V [2]. The PDGFRA 
D842V mutation confers imatinib resistance in  vitro as 
well as in clinical observations [1, 2, 5]. Due to rarity, 
other PDGFRA mutations have not been well character-
ized in individual treatment responsiveness, but collec-
tively are considered sensitive to imatinib therapy based 
on in  vitro data, clinical reports and improvement in 
outcomes in the “non-D842V PDGFRA mutation” catch-
all subset that is often used in reporting [2, 6]. For the 
rare PDGFRA exon 12 mutations, the largest retrospec-
tive series to date reported a 50  % objective response 
rate to imatinib in 8 GIST cases with an exon 12 muta-
tion [5]. Additionally, 1 of 1 patient with PDGFRA exon 
12 mutation on a phase III clinical trial, and 1 additional 
case report of GIST with exon 12 mutation noted a good 
response to imatinib [7, 8].
Sunitinib is commonly used as second line therapy for 
GIST after imatinib failure. Very few PDGFRA mutant 
GIST patients with sunitinib treatment outcomes 
have been reported to date and to our knowledge no 
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significant objective responses have been reported in this 
subset of GIST patients [5, 9–11]. The majority of PDG-
FRA mutations reported in these clinical series, however, 
have been of the D842V variety, which based on in vitro 
data would not be expected to have substantial activity to 
sunitinib treatment [11].
We report the case of a patient with PDGFRA exon 
12 mutated GIST. The mutation in our patient’s tumor 
results in an in-frame deletion of amino acids 559 and 
560, p.(W559-R560del). This deletion has not previously 
been reported, though is adjacent to a hotspot for muta-
tion in exon 12, V561D, and is partially overlapping with 
previously reported deletions [2, 12]. We report the clini-
cal responses to neoadjuvant imatinib as well as to sec-
ond line therapy for relapsed disease with sunitinib. To 
our knowledge this is the first case reporting on treat-
ment response of PDGFRA exon 12 mutated GIST in 
these two scenarios.
Case presentation
A 48-year-old male without significant past history was 
evaluated in December 2010 for abdominal pain. An 
abdominal sonogram showed a large heterogeneous mass 
originating from the stomach. PET/CT scan confirmed a 
21 × 13 × 9 cm gastric mass with moderate 18F-fluoro-
deoxyglucose (FDG) uptake, SUVmax 6.0. Endoscopic 
ultrasound with biopsy was performed January 2011 and 
pathology was consistent with a gastrointestinal stromal 
tumor (GIST). The patient was treated with neoadjuvant 
imatinib 400 mg daily. With treatment, the mass signifi-
cantly reduced in size to 9.2 × 6.8 × 4.9 cm on pre-oper-
ative imaging in September 2011. Laparoscopic resection 
was performed November 2011, with pathology confirm-
ing an 8.5  cm gastric GIST with focal myxoid changes 
and extensive post-treatment changes. No mitoses were 
identified in this post treatment specimen. Immunohis-
tochemistry was positive for CD117 and negative for 
CD34, S-100, SMA, desmin, and cytokeratin. Genetic 
testing was performed on the tumor specimen and it was 
found to lack KIT mutation by direct sequencing of exons 
9, 11, 13 and 17.
Our patient continued on treatment with adjuvant 
imatinib 400  mg daily despite having bothersome but 
low grade toxicity including fatigue, diarrhea, abdomi-
nal cramping, edema and joint pains. While still on adju-
vant imatinib, surveillance imaging in September 2013 
revealed a new 1.2 cm nodule in the mesentery. Follow-
up PET imaging showed mild FDG uptake, SUV 1.9. 
Resection was performed November 2013, and pathology 
was consistent with recurrent GIST measuring 1.7  cm. 
The post-surgical course was complicated by a sympto-
matic excisional hernia. At this recurrence, the resection 
specimen was sent for repeated gene mutation screening, 
this time for both KIT and PDGFRA, and an exon 12 
deletion, p.(W559-R560del), was detected in PDGFRA. 
No mutation was found in KIT. Resumption of kinase 
inhibitor therapy either at dose escalation [13] or switch 
to an alternate agent [14] was considered post-opera-
tively but was declined by the patient due to quality of life 
concerns.
In June 2014, CT imaging revealed a new 1.9 × 1.7 cm 
abdominal nodule abutting the undersurface on the left 
diaphragm, consistent with second recurrence. Laparo-
scopic resection with excisional hernia repair was under-
taken September 2014. During this procedure, the patient 
was noted to have two additional small tumor implants 
in the anterior abdominal wall. All three lesions were 
excised and consistent with metastatic GIST (Fig. 1). At 
post-operative restaging imaging done December 2014, 
the patient was noted to already have a new 4.2 cm liver 
lesion and a smaller 5 mm liver lesion. Shortly thereafter, 
he developed severe RUQ abdominal pain and was hospi-
talized for hemorrhage of the liver lesion and concurrent 
drop in hemoglobin requiring transfusion, but was man-
aged conservatively with resolution over several days.
The patient was started on systemic therapy for meta-
static disease with sunitinib 25  mg daily in January 
2015. A lower than typical starting dose of sunitinib was 
selected due to concern for potential toxicity in light of 
recent hemorrhage [14]. Prior to the start of therapy, he 
was restaged with PET/CT, showing FDG avid lesions in 
the liver dome (5.9 ×  5.1 cm, SUV 8.4) and a small left 
liver focus (sub-cm, SUVmax 5.2). There additionally was 
PET-avidity (SUVmax 5.9) in the anterior abdominal wall 
at the site of recent surgical resection and repair. On first 
restaging imaging after 10  weeks of treatment, PET/CT 
imaging revealed a dramatic improvement with the large 
hypermetabolic liver lesion no longer visible, nor was vis-
ible the smaller hepatic focus of FDG uptake (Fig. 2). The 
area of hypermetabolic activity in the anterior abdominal 
wall decreased in size and metabolic activity, radiograph-
ically favoring partial resolution of postoperative change 
though cannot rule out partial regression of metastatic 
disease. Sunitinib therapy is ongoing and has been well 
tolerated with grade 1 hypertension, grade 1 skin pal-
lor and grade 1–2 generalized fatigue noted as potential 
toxicities.
Conclusions
We report the case of a gastrointestinal stromal tumor 
with a previously unreported exon 12 deletion in PDG-
FRA. The patient was treated with neoadjuvant imatinib 
with reduction in size of the initial tumor from 21 cm in 
greatest dimension at the start of therapy to 8.5 cm at the 
time of resection. Responsiveness to imatinib is consist-
ent with a previous series that reported a 50 % response 
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rate to first line imatinib in a subset of 8 GIST patients 
with exon 12 PDGFRA mutation [5]. Unfortunately, 
despite a very good response to imatinib in the neoadju-
vant setting, our patient relapsed while still on continued 
adjuvant imatinib therapy. The approximate 2 year time 
between imatinib sensitivity and development of recur-
rence in our patient is similar to the typical time frame 
reported for the development of secondary imatinib 
resistance in the metastatic setting [11].
Most notably, we observed a striking response to treat-
ment with sunitinib in this patient with an exon 12 PDG-
FRA mutation, with complete resolution of two liver 
lesions at the time of first restaging. To our knowledge, 
this is the first reported objective response to sunitinib in 
PDGFRA mutated GIST in the literature. This favorable 
response is in conflict with the few previous reports on 
this subject, which have typically reported very limited 
efficacy of sunitinib in patients with PDGFRA mutated 
GIST [5, 9–11, 15]. The majority of PDGFRA mutations 
reported in these clinical series, however, have been of 
the D842V variety, which based on in  vitro data would 
not be predicted to have substantial activity to sunitinib 
treatment [11].
A limitation of our current report is that molecular 
testing in this case was restricted to that used for clinical 
practice and PDGFRA mutation testing was not imple-
mented on every specimen. At the time of initial resec-
tion, only KIT mutational testing was performed. It is 
therefore not definitive that the PDGFRA exon 12 dele-
tion was present at the time of initial imatinib response. 
Fig. 1 At low power (a, b, ×100), the metastatic GIST resected in 2014 demonstrated variable cellularity, with spindled to predominately epithelioid 
cells embedded within a myxoid stroma. On high power (c, ×400) cellular areas demonstrated sheets of epithelioid tumor cells with abundant 
cytoplasm and monotonous nuclei with finely granular chromatin, typical for epithelioid GIST. Scattered mitotic figures were present. Immunohisto-
chemical study for DOG1 (d, ×200) was diffusely positive in tumor cells
Page 4 of 5Brohl et al. Clin Sarcoma Res  (2015) 5:21 
Fig. 2 PET/CT imaging prior to (a–d) and after 10 weeks (e–h) of sunitinib therapy. Prior to treatment, whole body PET (a) revealed a large hyper-
metabolic lesion in the dome of the liver, a PET-avid sub-cm L hepatic lesion, and hypermetabolic activity in the abdominal wall near the site of 
previous surgical resection. On cross sectional CT imaging (b) the large hepatic lesion measured 5.9 × 5.1 cm in maximal dimension, and the cor-
responding area on PET imaging (c) and fused PET/CT (d) revealed an SUVmax of 8.4. Both liver lesions were no longer detectable on repeat imaging 
(e–h), and the surgical site hypermetabolic activity decreased (e), consistent with resolving post-operative changes
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PDGFRA exon 12 mutation, however, is most consistent 
with an imatinib-sensitive primary driver mutation [1, 2, 
5], rather than a secondary resistance mutation, which 
arise in the ATP binding pocket or loop domain of KIT or 
PDGFRA in response to the selective pressure of imatinib 
therapy [4, 15]. It is therefore likely that the PDGFRA 
mutation in our patient represents a primary driver 
mutation that was present throughout the disease course.
In summary, we report a dramatic response to sunitinib 
of a gastrointestinal stromal tumor with a rare exon 12 
PDGFRA mutation. Compared to the previous literature, 
our case highlights the substantial difference in clinical 
activity of this agent in different mutational subtypes of 
GIST, even within the narrower category of PDGFRA 
mutant GIST. Our report adds to the growing catalog of 
mutation-to-drug efficacy links and fills a knowledge gap 
in one of the rare molecular subtypes. Though confirma-
tory reports are needed, sunitinib should be considered 
for the rare patient with PDGFRA exon 12 mutated GIST.
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